These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28190247)

  • 21. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
    Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
    Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
    Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
    Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
    Jiang YZ; Yu KD; Bao J; Peng WT; Shao ZM
    Cancer Res; 2014 Jul; 74(13):3399-407. PubMed ID: 24924774
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study.
    Tjader NP; Beer AJ; Ramroop J; Tai MC; Ping J; Gandhi T; Dauch C; Neuhausen SL; Ziv E; Sotelo N; Ghanekar S; Meadows O; Paredes M; Gillespie JL; Aeilts AM; Hampel H; Zheng W; Jia G; Hu Q; Wei L; Liu S; Ambrosone CB; Palmer JR; Carpten JD; Yao S; Stevens P; Ho WK; Pan JW; Fadda P; Huo D; Teo SH; McElroy JP; Toland AE
    Cancer Res Commun; 2024 Jun; 4(6):1597-1608. PubMed ID: 38836758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.
    Bataillon G; Fuhrmann L; Girard E; Menet E; Laé M; Capovilla M; Treilleux I; Arnould L; Penault-Llorca F; Rouzier R; Marchiò C; Bieche I; Vincent-Salomon A
    Histopathology; 2018 Aug; 73(2):273-283. PubMed ID: 29537649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
    Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
    Savli H; Sertdemir N; Aydin D; Dursun B; Kurtas O; Reka S; Sunnetci-Akkoyunlu D; Eren-Keskin S; Uygun K; Ozden E; Isik U; Cabuk D; Demir G; Guzdolu E; Gokbayrak M; Aksu MG; Canturk NZ; Cine N
    J Biotechnol; 2019 Jul; 300():87-93. PubMed ID: 31100334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.
    Kadota M; Yang HH; Gomez B; Sato M; Clifford RJ; Meerzaman D; Dunn BK; Wakefield LM; Lee MP
    PLoS One; 2010 Feb; 5(2):e9201. PubMed ID: 20169162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
    Alvarez-Garcia V; Bartos C; Keraite I; Trivedi U; Brennan PM; Kersaudy-Kerhoas M; Gharbi K; Oikonomidou O; Leslie NR
    Sci Rep; 2018 Mar; 8(1):4290. PubMed ID: 29523855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
    Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
    BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
    Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
    Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revealing tumor heterogeneity of breast cancer by utilizing the linkage between somatic and germline mutations.
    Zou M; Jin R; Au KF
    Brief Bioinform; 2019 Nov; 20(6):2306-2315. PubMed ID: 30239581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Levels of Chromosomal Copy Number Alterations and TP53 Mutations Correlate with Poor Outcome in Younger Breast Cancer Patients.
    Koçak A; Heselmeyer-Haddad K; Lischka A; Hirsch D; Fiedler D; Hu Y; Doberstein N; Torres I; Chen WD; Gertz EM; Schäffer AA; Freitag-Wolf S; Kirfel J; Auer G; Habermann JK; Ried T
    Am J Pathol; 2020 Aug; 190(8):1643-1656. PubMed ID: 32416097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
    Al Zoubi MS; Otoum R; Alorjani MS; Al Bashir S; Al Trad B; Abualrja MI; Al-Khatib SM; Al-Batayneh K
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3365-3371. PubMed ID: 33247697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.